UQUIFA successfully renews its GMP Certificate
The UQUIFA GMP Certificate Renewal confirms our compliance with international Good Manufacturing Practice standards. UQUIFA has renewed its GMP certificate for the manufacture of the bulk intermediate product Pellets (non-sterile medicinal product for human use). The certificate is valid until 28 July 2028. This renewal reflects our commitment to safe, reliable and high-quality pharmaceutical manufacturing.
In addition, this achievement strengthens UQUIFA’s position as a trusted partner in the chemical–pharmaceutical sector. It also demonstrates the strength of our quality systems and our clear focus on regulatory excellence. We follow strict procedures to ensure consistency across production, documentation and operational control. As a result, every step in the process supports compliance and continuous improvement.
Our Commitment to Quality and Regulatory Compliance
At UQUIFA, maintaining GMP certification is essential to our work. It confirms that our manufacturing activities meet the standards required by regulators and customers. Moreover, it reflects our long-term dedication to quality, safety and transparency.
We apply rigorous controls, review our processes regularly and invest in training to ensure competence across all teams. In addition, we monitor performance indicators to identify opportunities for improvement. This approach allows us to deliver products that meet high pharmaceutical standards and support global supply chains.
Recognizing Our Team’s Contribution
The UQUIFA GMP Certificate Renewal is the result of the professionalism and discipline of our plant team. Their efforts ensure that our facilities remain compliant with GMP guidelines. Furthermore, their daily commitment strengthens our ability to operate safely and efficiently.
Strengthening Trust in Global Pharmaceutical Manufacturing
UQUIFA remains committed to delivering safe, high-quality and compliant products. Therefore, the renewal of our GMP certificate reinforces the trust of our clients, partners and stakeholders. We will continue to work with responsibility and excellence, ensuring strong performance across all operations and contributing to a reliable pharmaceutical supply chain.